急诊介入治疗联合不同剂量替罗非班对急性冠脉综合征患者疗效及安全性分析.docVIP

急诊介入治疗联合不同剂量替罗非班对急性冠脉综合征患者疗效及安全性分析 　　[摘要] 目的 分析经皮冠状动脉介入（PCI）联合不同剂量替罗非班对急性冠脉综合征（ACS）的疗效情况。 方法 方便选取2015年4月―2016年4月该院84例接受急诊PCI治疗的ACS患者分为两组，对照组及实验组，各42例；术中两组均先给予负荷剂量的替罗非班，之后，对照组及实验组分别按照0.15 μg/（kg?min）（全剂量）及0.075 μg/（kg?min）（半剂量）的速度持续泵入替罗非班；比较两组总有效率、心肌梗死溶栓（TIMI）血流分级、心血管事件（MACE）发生率。结果 对照组及实验组治疗总有效率分别为97.62%、95.24%，P0.05，差异无统计学意义。两组TIMI血流分级情况对比，P0.05，差异无统计学意义。此外，实验组MACE发生率略低于对照组（P0.05）。 结论 在应用PCI治疗ACS的过程中应用替罗非班的安全性较高，采用半剂量并不会增加MACE发生率。 　　[关键词] 经皮冠状动脉介入；替罗非班；急性冠脉综合征 　　[中图分类号] R541 [文献标识码] A [文章编号] 1674-0742（2016）11（a）-0129-03 　　[Abstract] Objective To analyse the effect of PCI combine with different doses of tirofiban in patients with ACS. Methods Convenient selection from April 2015 to April 2016， 84 cases of patients with ACS who underwent emergency PCI treatment were divided into the control group and the experimental group， 42 cases in each group. In the operation， the patients of two groups were applied the loading dose of tirofiban， after that the control group and the experimental group were applied tirofiban， respectively according to 0.15 μg/（kg?min）（full dose） and 0.075 μg/（kg?min）（half dose）.The total effective rate，flow grade of thrombolysis in myocardial infarction（TIMI） and major adverse cardiac event（MACE） rate of two groups were compared. Results The total effective rate of the control group and the experimental group respectively were97.62%，95.24% ， there were no statistically significant difference（P 0.05）. Flow grade of TIMI of two groups had no statistically significant difference（P 0.05）.In addition， the MACE rate of the experimental group was slightly lower than the control group（P 0.05）. Conclusion In the process of PCI in the treatment of ACS， tirofiban has high security， the half dose of it didn’t increase the rate of MACE. 　　[Key words] Percutaneous coronary intervention；Tirofiban； Acute coronary syndrome 　　ACS?倭俅渤＜?危急重症，该病具有发生率高、病死率高、预后差等特点，严重威胁患者生命健康。PCI是ACS的主要治疗方法，然而，相关报道指出，PCI术后急性血栓及亚急性血栓的发生率分别为16%、18%，严重影响患者预后[1]。可见，在PCI围手术期早期，预防性进行